🔎 Trials Near Me

Почетна › Акутна миелоидна леукемија › Пенсилванија › Philadelphia

Клинички испитувања за Акутна миелоидна леукемија во Philadelphia, PA

34 студии за Акутна миелоидна леукемија бараат учесници на локации во и околу Philadelphia (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.

Официјален текст на студијата (англиски)

Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Thomas Jefferson University Hospital, Philadelphia
Возраст 60 и постари · Сите полови · Ажурирано 5.10.2026 · NCT07437950

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Се регрутираФаза 2
  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
  • Thomas Jefferson University Hospital, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Се регрутираФаза 1
  • Children's Hospital of Philadelphia, Philadelphia
До возраст 21 · Сите полови · Ажурирано 5.10.2026 · NCT07012044

Assessment of Geriatric Evaluations Impact on New AML Guidance

Се регрутираНабљудувачка студија
  • Abramson Cancer Center at University of Pennsylvania, Philadelphia
Возраст 50 и постари · Сите полови · Ажурирано 2.10.2026 · NCT05909501

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
  • Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · на 22 милји
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Се регрутираНабљудувачка студија
  • Children's Hospital of Philadelphia, Philadelphia
Возраст од 0 до 38 · Сите полови · Ажурирано 1.10.2026 · NCT06131801

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Се регрутираФаза 3
  • Thomas Jefferson University, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06852222

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Thomas Jefferson University Hospital, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
  • Thomas Jefferson University Hospital, Philadelphia
Возраст од 18 до 59 · Сите полови · Ажурирано 22.9.2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Се регрутираФаза 3
  • Children's Hospital of Philadelphia, Philadelphia
  • Saint Christopher's Hospital for Children, Philadelphia
  • Alfred I duPont Hospital for Children, Wilmington · на 25 милји
6 Months – 21 Years · Сите полови · Ажурирано 17.9.2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Се регрутираФаза 1/2
  • University of Pennsylvania, Philadelphia
30 Days · Сите полови · Ажурирано 16.9.2026 · NCT04065399

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Се регрутираФаза 1
  • UPENN Perelman Center for Advanced Medicine, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06846606

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Се регрутираФаза 3
  • Children's Hospital of Philadelphia, Philadelphia
  • Alfred I duPont Hospital for Children, Wilmington · на 25 милји
Возраст од 1 до 25 · Сите полови · Ажурирано 4.9.2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Се регрутираФаза 1/2
  • Children's Hospital of Philadelphia, Philadelphia
  • Saint Christopher's Hospital for Children, Philadelphia
  • Alfred I duPont Hospital for Children, Wilmington · на 25 милји
До возраст 22 · Сите полови · Ажурирано 25.8.2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Се регрутираФаза 3
  • Children's Hospital of Philadelphia, Philadelphia
  • Nemours Alfred I. Dupont Hospital for Children, Wilmington · на 25 милји
29 Days – 21 Years · Сите полови · Ажурирано 24.8.2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Се регрутираФаза 3
  • University of Pennsylvania, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 20.8.2026 · NCT07007312

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Се регрутираФаза 2/3
  • University of Pennsylvania, Philadelphia
Возраст од 18 до 80 · Сите полови · Ажурирано 5.8.2026 · NCT06788756

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Се регрутираФаза 1
  • Children's Hospital of Philadelphia, Philadelphia
Возраст од 1 до 30 · Сите полови · Ажурирано 3.8.2026 · NCT06177067

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Се регрутираФаза 2
  • Penn Medicine Abramson Cancer Center, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 10.7.2026 · NCT05442216

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

Се регрутираФаза 1
  • University of Pennsylvania, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 9.7.2026 · NCT05945849

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Се регрутира
  • Children's Hospital of Philadelphia, Philadelphia
До возраст 25 · Сите полови · Ажурирано 8.7.2026 · NCT03810196

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Се регрутираФаза 1
  • Children's Hospital of Philadelphia, Philadelphia
Возраст од 0 до 29 · Сите полови · Ажурирано 7.7.2026 · NCT07464951

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Се регрутираНабљудувачка студија
  • Children's Hospital of Philadelphia, Philadelphia
  • Nemours - Alfred I. duPont Hospital for Children, Brandywine · на 21 милји
Сите возрасти · Сите полови · Ажурирано 6.7.2026 · NCT01351545

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Се регрутираФаза 1/2
  • Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 24.6.2026 · NCT04068597

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Се регрутираФаза 1
  • University of Pennsylvania, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 14.5.2026 · NCT06222580

Massage Impact on Sleep in Pediatric Oncology

Се регрутира
  • Children's Hospital of Philadelphia, Philadelphia
Возраст од 12 до 21 · Сите полови · Ажурирано 15.4.2026 · NCT06892158

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Се регрутираФаза 1/2
  • Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Возраст 12 и постари · Сите полови · Ажурирано 24.3.2026 · NCT04988555

Phase IB/II of CPX-351 for Relapse Prevention in AML

Се регрутираФаза 1/2
  • University of Pennsylvania, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 23.3.2026 · NCT04990102

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Се регрутираФаза 1
  • Thomas Jefferson University Hospital, Philadelphia
Возраст 12 и постари · Сите полови · Ажурирано 16.3.2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Се регрутираФаза 1
  • Hospital of the University of Pennsylvania, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 13.3.2026 · NCT05735184

Tazemetostat and Palbociclib With CPX-351for R/R AML

Се регрутираФаза 1
  • Thomas Jefferson University Hospital, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 12.3.2026 · NCT05627232

Home Blood Transfusions

Се регрутира
  • Thomas Jefferson University Hospital, Philadelphia
Возраст 18 и постари · Сите полови · Ажурирано 16.12.2025 · NCT07121140

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Се регрутираДобредојдени се здрави волонтери
  • University of Pennsylvania, Philadelphia
Возраст од 18 до 120 · Сите полови · Ажурирано 25.7.2025 · NCT05237258

Испитувања за Акутна миелоидна леукемија во други градови

Други студии во Philadelphia

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.